Picture of Eurofins-Cerep SA logo

ALECR Eurofins-Cerep SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-4.25%
3m-16.58%
6m-27.01%
1yr-18.58%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital13.36%
Return on Equity16.58%
Operating Margin17.86%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Eurofins-Cerep SA EPS forecast chart

Profile Summary

Eurofins-Cerep SA, formerly Cerep SA is a France-based company that specializes in the pre-clinical research, discovery and development of new pharmaceutical drugs. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The Company then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
January 22nd, 1990
Public Since
March 19th, 2010
No. of Employees
233
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
5,044

ALECR Share Price Performance

Upcoming Events for ALECR

Eurofins-Cerep SA Annual Shareholders Meeting

Similar to ALECR

Picture of Abionyx Pharma SA logo

Abionyx Pharma SA

fr flag iconEuronext - Paris

Picture of Abivax SA logo

Abivax SA

fr flag iconEuronext - Paris

Picture of Acticor Biotech SA logo

Acticor Biotech SA

fr flag iconEuronext - Paris

Picture of Adocia SA logo

Adocia SA

fr flag iconEuronext - Paris

Picture of Biophytis SA logo

Biophytis SA

fr flag iconEuronext - Paris

FAQ